Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges

Tuberculosis infection (TBI) is defined as a state of infection in which individuals host live Mycobacterium tuberculosis with or without clinical signs of active TB. It is now understood as a dynamic process covering a spectrum of responses to infection resulting from the interaction between the TB bacilli and the host immune system. The global burden of TBI is about one-quarter of the world’s population, representing a reservoir of approximately 2 billion people. On average, 5–10% of people who are infected will develop TB disease over the course of their lives, but this risk is enhanced in a series of conditions, such as co-infection with HIV. The End-TB strategy promotes the programmatic management of TBI as a crucial endeavor to achieving global targets to end the TB epidemic. The current development of new diagnostic tests capable of discriminating between simple TBI and active TB, combined with novel short-course preventive treatments, will help achieve this goal. In this paper, we present the current situation and recent developments of management of TBI and the operational challenges.


Introduction
Tuberculosis (TB) is a major, yet preventable, global health problem [1].According to the World Health Organization (WHO), in 2021, TB was among the top ten causes of death worldwide and the second leading cause of death from a single infectious agent, after COVID-19 [1].The WHO estimated that 10.6 million people had developed active TB worldwide in 2021 and 1.6 million had died from it [1].

died from it
[1].

TB infection (TBI) is defined as a state of persistent immune response to stimulation by M. tuberculosis (M.tb) antigens with or without evidence of the clinical manifestation of active TB [2].Most infected people have no clinical signs or symptoms and are not contagious, but they are at risk of progression to avert active TB, at which time they can contribute to transmission.On average, TB infection (TBI) is defined as a state of persistent immune response to stimulation by M. tuberculosis (M.tb) antigens with or without evidence of the clinical manifestation of active TB [2].Most infected people have no clinical signs or symptoms and are not contagious, but they are at risk of progression to avert active TB, at which time they can contribute to transmission.On average, 5-10% of people who are infected will develop active TB over the course of their lives, with the highest risk in the first year after infection [3].According to a recent re-estimation [4], the global burden of TBI is about one-quarter of the world's population, representing a reservoir of approximately 2 billion people.People at extreme ages of life, people with compromised immune systems such as people living with HIV (PLHIV) or those who have a co-morbid condition such as malnutrition or diabetes, have a higher risk of progressing to active TB, with rates reaching as high as 10% per year among PLHIV [5].
-10% of people who are infected will develop active TB over the course of their lives, with the highest risk in the first year after infection [3].According to a recent re-estimation [4], the global burden of TBI is about one-quarter of the world's population, representing a reservoir of approximately 2 billion people.People at extreme ages of life, people with compromised immune systems such as people living with HIV (PLHIV) or those who have a co-morbid condition such as malnutrition or diabetes, have a higher risk of progressing to active TB, with rates reaching as high as 10% per year among PLHIV [5].

In 2014, the World Health Assembly endorsed the 'End-TB strategy' [6] that aims to end the global TB epidemic by 2035, by reducing TB deaths by 95%, cutting down new cases by 90% and ensuring that no family faces catastrophic costs due to TB [6].For the first time ever, this strategy promotes the management of TBI as a crucial endeavor to achieving global targets to end the TB epidemic.This l In 2014, the World Health Assembly endorsed the 'End-TB strategy' [6] that aims to end the global TB epidemic by 2035, by reducing TB deaths by 95%, cutting down new cases by 90% and ensuring that no family faces catastrophic costs due to TB [6].For the first time ever, this strategy promotes the management of TBI as a crucial endeavor to achieving global targets to end the TB epidemic.This led the WHO to update recommendations on TB prevention and control in 2019 so as to provide comprehensive guidance on the management of TBI in high-and low-TB-burden countries [7].
d the WHO to update recommendations on TB prevention and control in 2019 so as to provide comprehensive guidance on the management of TBI in high-and low-TB-burden countries [7].

In this paper, we aim to provide an overview of the situation of TBI worldwide and present the current intervention strategies and recommendations for TB prevention in highand low-TB-burden countries.


The Landscape of TBI Prevention in High-and Low-Burden Countries


The Evolving Concept of TBI

For decades, the outcome of infection by M.tb was represented as a bimodal distribution between la In this paper, we aim to provide an overview of the situation of TBI worldwide and present the current intervention strategies and recommendations for TB prevention in highand low-TB-burden countries.

The Evolving Concept of TBI
For decades, the outcome of infection by M.tb was represented as a bimodal distribution between latent and active TB (disease), based on the presence or absence of clinical symptoms and reaction to tuberculin skin testing.Since the beginning of the 21st century, TBI has been increasingly conceptualized as a dynamic and continuous spectrum of response to infection resulting from the interaction between TB bacilli and the host immune system [8].Indeed, recent research suggests that asymptomatic people considered to have TBI might be distributed along a wide spectrum of infection states, where at one end, infection may have been eliminated, while at the other end, active TB may be already present but in a subclinical form, and between these two extremes, infection is variably controlled in a quiescent state [8,9].Subsequently, as illustrated in Figure 1, the risk of developing active TB varies along this spectrum, depending on the balance of bacterial replication and efficacy of the host's immune response [10].Thus, at one end of the spectrum are the persons in whom infection is contained either through innate immune response or acquired T-cell immunity, while at the other end are persons with "incipient" TB [11], defined as infection with viable M.tb bacteria that has not yet caused clinical symptoms, radiographic abnormalities or microbiological evidence consistent with active TB, but who may be more likely to progress to active disease [12].Incipient patients would be an attractive group to target TB preventive treatment (TPT) [13,14].first time ever, this strategy promotes the management of TBI as a crucial endeavor to achieving global targets to end the TB epidemic.This led the WHO to update recommendations on TB prevention and control in 2019 so as to provide comprehensive guidance on the management of TBI in high-and low-TB-burden countries [7].
ent and active TB (disease), based on the presence or absence of clinical symptoms and reaction to tuberculin skin testing.Since the beginning of the 21st century, TBI has been increasingly conceptuali

ulting from the interaction
etween TB bacilli and the host immune system [8].Indeed, recent research suggests that asymptomatic people considered to have TBI might be distributed along a wide spectrum of infection states, where at one end, infection may have been eliminated, while at the other end, active TB may be already present but in a subclinical form, and between these two extremes, infection is variably controlled in a quiescent state [8,9].Subsequently, as illustrated in Figure 1, the risk of developing active TB varies along this spectrum, depending on the balance of bacterial replication and efficacy of the host's immune response [10].Thus, at one end of the spectrum are the persons in whom infection is contained either through innate immune response or acquired T-cell immunity, while at the other end are persons with "incipient" TB [11], defined as infection with viable M.tb bacteria that has not yet caused clinical symptoms, radiographic abnormalities or microbiological evidence consistent with active TB, but who may be more likely to progress to active disease [12].Incipient patients would be an attractive group to target TB preventive treatment (TPT) [13,14].first time ever, this strategy promotes the management of TBI as a crucial endeavor to achieving global targets to end the TB epidemic.This led the WHO to update recommendations on TB prevention and control in 2019 so as to provide comprehensive guidance on the management of TBI in high-and low-TB-burden countries [7].

In this paper, we aim to provide an overview of the situation of TBI worldwide and present the current intervention strategies and recommendations for TB prevention in high-and low-TB-burden countries.


The Landscape of TBI Prevention in High-and Low-Burden Countries


The Evolving Concept of TBI

For decades, the outcome of infection by M.tb was represented as a bimodal distribution between latent and active TB (disease), based on the presence or absence of clinical symptoms and reaction to tuberculin skin testing.Since the beginning of the 21st century, TBI has been increasingly conceptualized as In this paper, we aim to provide an overview of the situation of TBI worldwide and present the current intervention strategies and recommendations for TB prevention in high-and low-TB-burden countries.

The Evolving Concept of TBI
For decades, the outcome of infection by M.tb was represented as a bimodal distribution between latent and active TB (disease), based on the presence or absence of clinical symptoms and reaction to tuberculin skin testing.Since the beginning of the 21st century, TBI has been increasingly conceptualized as a dynamic and continuous spectrum of response to infection resulting from the interaction between TB bacilli and the host immune system [8].Indeed, recent research suggests that asymptomatic people considered to have TBI might be distributed along a wide spectrum of infection states, where at one end, infection may have been eliminated, while at the other end, active TB may be already present but in a subclinical form, and between these two extremes, infection is variably controlled in a quiescent state [8,9].Subsequently, as illustrated in Figure 1, the risk of developing active TB varies along this spectrum, depending on the balance of bacterial replication and efficacy of the host's immune response [10].Thus, at one end of the spec- trum are the persons in whom infection is contained either through innate immune response or acquired T-cell immunity, while at the other end are persons with "incipient" TB [11], defined as infection with viable M.tb bacteria that has not yet caused clinical symptoms, radiographic abnormalities or microbiological evidence consistent with active TB, but who may be more likely to progress to active disease [12].Incipient patients would be an attractive group to target TB preventive treatment (TPT) [13,14].

from the interaction betwee
TB bacilli and the host immune system [8].Indeed, recent research suggests that asymptomatic people considered to have TBI might be distributed along a wide spectrum of infection states, where at one end, infection may have been eliminated, while at the other end, active TB may be already present but in a subclinical form, and between these two extremes, infection is variably controlled in a quiescent state [8,9].Subsequently, as illustrated in Figure 1, the risk of developing active TB varies along this spectrum, depending on the balance of bacterial replication and efficacy of the host's immune response [10].Thus, at one end of the spec- trum are the persons in whom infection is contained either through innate immune response or acquired T-cell immunity, while at the other end are persons with "incipient" TB [11], defined as infection with viable M.tb bacteria that has not yet caused clinical symptoms, radiographic abnormalities or microbiological evidence consistent with active TB, but who may be more likely to progress to active disease [12].Incipient patients would be an attractive group to target TB preventive treatment (TPT) [13,14].


Global Burden

As mentioned above, about a quarter of the world's population is estimated to be infected with M.tb [4,15].Indeed, the global TBI prevalence was reported to be 23.0% in 2014 [4], and 24.8% (using interferon-gamma release assay) and 21.2% (using tuberculin skin test) in 2018 [15].In the WHO regions, the estimated prevalence of TBI in 2018 was


Global Burden

As mentioned above, about a qu

Global Burden
As mentioned above, about a quarter of the world's population is estimated to be infected with M.tb [4,15].Indeed, the global TBI prevalence was reported to be 23.0% in 2014 [4], and 24.8% (using interferon-gamma release assay) and 21.2% (using tuberculin skin test) in 2018 [15].In the WHO regions, the estimated prevalence of TBI in 2018 was

Global Burden
As mentioned above, about a quarter of the world's population is estimated to be infected with M.tb [4,15].Indeed, the global TBI prevalence was reported to be 23.0% in 2014 [4], and 24.8% (using interferon-gamma release assay) and 21.2% (using tuberculin skin test) in 2018 [15].In the WHO regions, the estimated prevalence of TBI in 2018 was 36% in South-East Asia, 34% in Africa, 24% in the Eastern Mediterranean, 21% in the Western Pacific, 14% in the Americas and 12% in Europe [15].The top three countries with the highest TBI burden from 1990 to 2019 were China, India and Indonesia [16].

ter of the wor
d's population is estimated to be infected with M.tb [4,15].Indeed, the global TBI prevalence was reported to be 23.0% in 2014 [4], and 24.8% (using interferon-gamma release assay) and 21.2% (using tuberculin skin test) in 2018 [15].In the WHO regions, the estimated prevalence of TBI in 2018 was 36% in South-East Asia, 34% in Africa, 24% in the

stern Mediterr
nean, 21% in the Western Pacific, 14% in the Americas and 12% in Europe [15].The top three countries with the highest TBI burden from 1990 to 2019 were China, India and Indonesia [16].

Data on the prevalence of infection with strains that are resistant to first line anti-TB drugs (isoniazid and/or rifampicin) are not available, as infecting strains of M.tb cannot be isolated and tested for resistance.It has been estimated that about 11% of infections occurring in the world are due to an isoniazid-resistant M.tb strain [11].A mathematical model, using cohorts tracked over time and historical Data on the prevalence of infection with strains that are resistant to first line anti-TB drugs (isoniazid and/or rifampicin) are not available, as infecting strains of M.tb cannot be isolated and tested for resistance.It has been estimated that about 11% of infections occurring in the world are due to an isoniazid-resistant M.tb strain [11].A mathematical model, using cohorts tracked over time and historical data on the annual risk of infection, estimated that globally, 19.1 million people were latently infected with MDR-TB strains in 2014 [17].MDR-TB strains accounted for 1.2% (95%CI 1.0-1.4) of the total burden of TBI overall, with a double burden in children younger than 15 years [17].This has public health implications since either isoniazid monotherapy or combinations of isoniazid and rifamycin are not likely to be effective for TB prevention in these individuals.
ata on the annual risk of infection, estimated that globally, 19.1 million people were latently infected with MDR-TB strains in 2014 [17].MDR-TB strains accounted for 1.2% (95%CI 1.0-1.4) of the total burden of TBI overall, with a double burden in children younger than 15 years [17].This has public health implications since either isoniazid monotherapy or combinations of isoniazid and rifamycin are not likely to be effective for TB prevention in these individuals.


Target Population

Not all individuals infected with M.tb ultimately progress to active TB, but the risk of the development of the disease varies according to individuals.It is therefore legitimate, from a public health point of view, to identify populations that are the most at risk of active TB for routine TB screening and provision of TPT.The proportion of individuals who will develop (over 2-years follow-up)

Target Population
Not all individuals infected with M.tb ultimately progress to active TB, but the risk of the development of the disease varies according to individuals.It is therefore legitimate, from a public health point of view, to identify populations that are the most at risk of active TB for routine TB screening and provision of TPT.The proportion of individuals who will develop (over 2-years follow-up) active TB after TBI is particularly high in children and immunocompromised individuals [2].Among children who have not received TPT, this proportion is 40-50% in infants younger than 12 months, decreases to 25% in children between 1 and 2 years of age, falls to 5-10% in school-aged children and then increases to 10-15% in adolescents [18].On average, PLHIV TB co-infections have an 18-fold (95% CI: 15-21) higher risk of developing active TB than HIV-negative people [19].This risk remains significantly high even after successful antiretroviral therapy (ART) [20,21]: PLHIV under ART were reported to have a 25% higher risk of active TB compared to HIV-negative people (active TB incidence rates (cases/100 person-year, [95% CI]) 2.70, [1.73-4.47] vs. 0.62, [0.58-0.65],respectively) [22].For these reasons, the WHO recommends that PLHIV (>12 months of age) regardless of TB exposure, should be prioritized for receiving TPT after formally excluding active TB, even in the absence of TBI confirmation [23,24].

tive TB after TBI
s particularly high in children and immunocompromised individuals [2].Among children who have not received TPT, this proportion is 40-50% in infants younger than 12 months, decreases to 25% in children between 1 and 2 years of age, falls to 5-10% in school-aged children and then increases to 10-15% in adolescents [18].On average, PLHIV TB co-infections have an 18-fold (95% CI: 15-21) higher risk of developing active TB than HIV-negative people [19].This risk remains significantly high even after successful antiretroviral therapy (ART) [20,21]: PLHIV under ART were reported to have a 25% higher risk of active TB compared to HIV-negative people (active TB incidence rates (cases/100 person-year, [95% CI]) 2.70, [1.73-4.47] vs. 0.62, [0.58-0.65],respectively) [22].For these reasons, the WHO recommends that PLHIV (>12 months of age) regardless of TB exposure, should be prioritized for receiving TPT after formally excluding active TB, even in the absence of TBI confirmation [23,24].

Household contacts (HHCs) of bacteriologically confirmed TB cases are another target population.A meta-analysis of prospective cohort studies of TB-exposed children showed that children with a positive TBI Household contacts (HHCs) of bacteriologically confirmed TB cases are another target population.A meta-analysis of prospective cohort studies of TB-exposed children showed that children with a positive TBI test not receiving TPT had a significantly higher cumulative incidence of active TB in the first 2 years of follow-up than children with a negative test result.The 2-year cumulative incidence decreased with the children's age: 19.0% [95% CI 8.4-37.4]for <5 years; 9.0% [95% CI 4.0-20.0]for 5-9 years; 8.8% [95% CI 4.0-19.8]for 10-14 years; and 10.5% [95% CI 4.9-23.1]for 15-18 years [25].The effectiveness of TPT was 63% (adjusted hazard ratio (HR) 0.37; 95% CI 0.30-0.47]) in all exposed children and 91% (adjusted HR 0.09; 95% CI 0.05-0.15) in those with a positive result for TBI testing [25].Another systematic review of HHCs in high-TB-burden countries showed that all HHCs, regardless of age or TBI status, have a higher risk of progression to active TB than the general population (relative risk (RR): 24.7, 95% CI 14.2-43.0)[26].For these reasons, the current WHO guidelines recommend the provision of TPT to all HHCs regardless of age after excluding active TB, with a priority to contacts < 5 years old and HIV-positive contacts > 5 years old, with no need to systematically confirm TBI [23,24].
est not receiving TPT had a significantly higher cumulative incidence of active TB in the first 2 years of follow-up than children with a negative test result.The 2-year cumulative incidence decreased with the children's age: 19.0% [95% CI 8.4-37.4]for <5 years; 9.0% [95% CI 4.0-20.0]for 5-9 years; 8.8% [95% CI 4.0-19.8]for 10-14 years; and 10.5% [95% CI 4.9-23.1]for 15-18 years [25].The effectiveness of TPT was 63% (adjusted hazard ratio (HR) 0.37; 95% CI 0.30-0.47]) in all exposed children and 91% (adjusted HR 0.09; 95% CI 0.05-0.15) in those with a positive result for TBI testing [25].Another systematic review of HHCs in high-TB-burden countries showed that all HHCs, regardless of age or TBI status, have a higher risk of progression to active TB than the general population (relative risk (RR): 24.7, 95% CI 14.2-43.0)[26].For these reasons, the current WHO guidelines recommend the provision of TPT to all HHCs regardless of age after excluding active TB, with a priority to contacts < 5 years old and HIV-positive contacts > 5 years old, with no need to systematically confirm TBI [23,24].

Lastly, TPT should be considered in other groups at high risk of TBI and/or progression to active TB [2,23,24].These are migrants from countries with a high TB burden; homeless persons; prisoners; illicit-drug users; Lastly, TPT should be considered in other groups at high risk of TBI and/or progression to active TB [2,23,24].These are migrants from countries with a high TB burden; homeless persons; prisoners; illicit-drug users; patients receiving immunosuppressive therapy including TNFα inhibitors, long-term corticotherapy or undergoing hemodialysis; organ transplantation; elderly individuals; those with associated broncho-pulmonary disease, such as silicosis in miners; and health care workers.
patients receiving immunosuppressive therapy including TNFα inhibitors, long-term corticotherapy or undergoing hemodialysis; organ transplantation; elderly individuals; those with associated broncho-pulmonary disease, such as silicosis in miners; and health care workers.


TBI and COVID-19 Pandemic

The COVID-19 pandemic has severely affected the routine TB services due to the reduction in health systems' capacity, the reassignment of health care workers to COVID-19 activities, the rea

TBI and COVID-19 Pandemic
The COVID-19 pandemic has severely affected the routine TB services due to the reduction in health systems' capacity, the reassignment of health care workers to COVID-19 activities, the reallocation of TB diagnostic resources to COVID-19 and stigma associated with similarities in the symptoms related to TB and COVID-19 [19].Implementation of lockdowns and strict quarantine measures resulted in delays in TB diagnosis, disruptions in contact-tracing activities and initiation of TPT and possibly increased transmission of TB within households [19].The WHO reported an unprecedented drop in global TB case notifications between 2019 and 2020 (from 7.1 million to 5.8 million), with the largest reductions in the South-East Asia and Western Pacific regions [19].In addition, the gap between the number of new TB duly notified cases and the estimated number of new cases has been shown to increase from 3.2 million in 2019 to 4.2 million people in 2021 [1,27].In parallel, the number of people initiated on TPT decreased by 21% from 3.6 million in 2019 to 2.8 million in 2020 [19].

ocation of TB diagnostic r
sources to COVID-19 and stigma associated with similarities in the symptoms related to TB and COVID-19 [19].Implementation of lockdowns and strict quarantine measures resulted in delays in TB diagnosis, disruptions in contact-tracing activities and initiation of TPT and possibly increased transmission of TB within households [19].The WHO reported an unprecedented drop in global TB case notifications between 2019 and 2020 (from 7.1 million to 5.8 million), with the largest reductions in the South-East Asia and Western Pacific regions [19].In addition, the gap between the number of new TB duly notified cases and the estimated number of new cases has been shown to increase from 3.2 million in 2019 to 4.2 million people in 2021 [1,27].In parallel, the number of people initiated on TPT decreased by 21% from 3.6 million in 2019 to 2.8 million in 2020 [19].

However, in the context of the disruption of essential TB services due to the COVID-19 pandemic, it is worth mentioning some successes in the implementation of innovative responses to TB [19,28].These include multi-diseas However, in the context of the disruption of essential TB services due to the COVID-19 pandemic, it is worth mentioning some successes in the implementation of innovative responses to TB [19,28].These include multi-disease screening and testing strategies (GeneXpert for TB and COVID-19); automated chest X-ray interpretation and cough detection technologies at the point-of-care; and a shift from vertical to integrated approaches such as the use of community health workers to improve early TB case detection, diagnosis and care [19, 27,28]; as well as the definition of a roadmap for access to the preventive screening of vulnerable populations in developed countries in line with the principles of universal health coverage [29].Regarding TBI prevention, the COVID-19 pandemic has led to improvements in infection prevention and control within health systems, including the increased use of masks by patients and personal protective equipment by health care providers, resulting in a reduction in nosocomial transmission of both COVID-19 and TBI [30].
screening and testing strategies (GeneXpert for TB and COVID-19); automated chest X-ray interpretation and cough detection technologies at the point-of-care; and a shift from vertical to integrated approaches such as the use of community health workers to improve early TB case detection, diagnosis and care [19, 27,28]; as well as the definition of a roadmap for access to the preventive screening of vulnerable populations in developed countries in line with the principles of universal health coverage [29].Regarding TBI prevention, the COVID-19 pandemic has led to improvements in infection prevention and control within health systems, including the increased use of masks by patients and personal protective equipment by health care providers, resulting in a reduction in nosocomial transmission of both COVID-19 and TBI [30].


Recent Developments in TBI Management


TBI Diagnosis

Identifying individuals with TBI at high risk of progression to active TB remains a challenge.There are two main diagnosis tests for TBI in use currently: the tubercu

TBI Diagnosis
Identifying individuals with TBI at high risk of progression to active TB remains a challenge.There are two main diagnosis tests for TBI in use currently: the tuberculin skin test (TST) and the interferon-gamma release assays (IGRAs) [31].Both tests are indirect tests based on the immune response to TB and do not directly assess the presence or viability of M.tb [32].In addition, both tests cannot differentiate between different stages of TBI and have a low positive predictive value for progression to active disease [31], implying that a high number of people should be theoretically treated to prevent a case of active TB [33].This may be problematic given the non-negligible risk of potential treatment-related adverse effects such as hepatotoxicity.

ma release ass
ys (IGRAs) [31].Both tests are indirect tests based on the immune response to TB and do not directly assess the presence or viability of M.tb [32].In addition, both tests cannot differentiate between different stages of TBI and have a low positive predictive value for progression to active disease [31], implying that a high number of people should be theoretically treated to prevent a case of active TB [33].This may be problematic given the non-negligible risk of potential treatment-related adverse effects such as hepatotoxicity.

Among the newer TBI tests, the IGRA QuantiFERON-TB Plus (QFT-Plus) contains new antigens optimized for CD4+ and CD8+ T cell stimulation compared to the former QFT-Gold In-Tube (QFT-GIT) [34].QFT-Plus has the potential to indic Among the newer TBI tests, the IGRA QuantiFERON-TB Plus (QFT-Plus) contains new antigens optimized for CD4+ and CD8+ T cell stimulation compared to the former QFT-Gold In-Tube (QFT-GIT) [34].QFT-Plus has the potential to indicate recent infection and disease activity, by measuring the level of immune response.A recent meta-analysis found that QFT-Plus is a more sensitive test than QFT-GIT for detecting M.tb infection [35].In 2019, Lionex GmbH introduced another new IGRA test (LIOFeron TB/TBI test), that may have higher sensitivity than the QFT-Plus assay [36,37].The C-Tb assay is a novel skin test using the ESAT-6 and CFP-10 antigens, classically used in IGRA tests.This assay aims to combine the operational advantages of TST with the performance characteristics of IGRA.The C-Tb assay performed better than the TST in BCG-vaccinated individuals, had high concordance with the QFT-GIT test and was found to be safe in PLHIV and children under 5 years of age, with a similar positivity rate to the QFT test [38].According to the WHO, this new type of M.tb antigen-based skin test is cost-effective or cost-saving as compared to TST and IGRA [39].However, new IGRAs are more specific than new TST (C-Tb assay), as they detect only TB-specific responses and do not cross-react with other mycobacteria and BCG.Additionally, IGRAs seem to be less affected by immunosuppression because they are able to measure a broader range of immune responses [40].Ultimately, the choice of test will depend on the clinical context and the availability of the test as well as the local epidemiology of TB (high-or low-TB incidence, proportion of BCG-vaccinated population) when selecting a diagnostic test for TBI [41].
te recent infection and disease activity, by measuring the level of immune response.A recent meta-analysis found that QFT-Plus is a more sensitive test than QFT-GIT for detecting M.tb infection [35].In 2019, Lionex GmbH introduced another new IGRA test (LIOFeron TB/TBI test), that may have higher sensitivity than the QFT-Plus assay [36,37].The C-Tb assay is a novel skin test using the ESAT-6 and CFP-10 antigens, classically used in IGRA tests.This assay aims to combine the operational advantages of TST with the performance characteristics of IGRA.The C-Tb assay performed better than the TST in BCG-vaccinated individuals, had high concordance with the QFT-GIT test and was found to be safe in PLHIV and children under 5 years of age, with a similar positivity rate to the QFT test [38].According to the WHO, this new type of M.tb antigen-based skin test is cost-effective or cost-saving as compared to TST and IGRA [39].However, new IGRAs are more specific than new TST (C-Tb assay), as they detect only TB-specific responses and do not cross-react with other mycobacteria and BCG.Additionally, IGRAs seem to be less affected by immunosuppression because they are able to measure a broader range of immune responses [40].Ultimately, the choice of test will depend on the clinical context and the availability of the test as well as the local epidemiology of TB (high-or low-TB incidence, proportion of BCG-vaccinated population) when selecting a diagnostic test for TBI [41].


Blood Biomarkers for Incipient TB

The key purpose of diagnosing TBI is to identify persons who are most likely to progress to active TB [42].Incipient TB is an attractive target for the development of new diagnostics.Whole blood bioma

Blood Biomarkers for Incipient TB
The key purpose of diagnosing TBI is to identify persons who are most likely to progress to active TB [42].Incipient TB is an attractive target for the development of new diagnostics.Whole blood biomarkers that can best predict the risk of progression to active TB are being tested using RNA sequencing in the blood of exposed persons, and studies identified genetic signatures for a risk of progression to TB disease within 6 to 12 months [43][44][45][46].Recently, a three-gene signature set was shown to distinguish active TB from TBI and to correctly classify 91.5% of individuals (compared to 80-85% for previous tested signatures [47,48]).The diagnostic performance of this three-gene signature was tested in a clinical cohort of 147 subjects with suspected active TB, and the sensitivity and specificity for active TB were 82.4 and 92.4%, respectively [44] (compared to 71 and 89% for former signatures [47]).

ers that can best predict the risk
of progression to active TB are being tested using RNA sequencing in the blood of exposed persons, and studies identified genetic signatures for a risk of progression to TB disease within 6 to 12 months [43][44][45][46].Recently, a three-gene signature set was shown to distinguish active TB from TBI and to correctly classify 91.5% of individuals (compared to 80-85% for previous tested signatures [47,48]).The diagnostic performance of this three-gene signature was tested in a clinical cohort of 147 subjects with suspected active TB, and the sensitivity and specificity for active TB were 82.4 and 92.4%, respectively [44] (compared to 71 and 89% for former signatures [47]).

Despite these advances, currently no diagnostic test can accurately detect TBI, or distinguish subclinical or early clinical disease from TBI, nor identify TBI due to drugresistant strains of M.tb [49].


Tuberculosis Preventive Treatment Despite these advances, currently no diagnostic test can accurately detect TBI, or distinguish subclinical or early clinical disease from TBI, nor identify TBI due to drugresistant strains of M.tb [49].

Tuberculosis Preventive Treatment
For more than 50 years, isoniazid has been the main drug used for TPT.However, the 6-to 9-month isoniazid regimen has shown low acceptance and completion rates, due to the long treatment duration, poor treatment adherence and poor tolerability [50][51][52].
or more than 50 years, isoniazid has been the main drug used for TPT.However, the 6-to 9-month isoniazid regimen has shown low acceptance and completion rates, due to the long treatment duration, poor tr

tment adherence and poor tolerabil
ty [50][51][52].

Over the last decade, new treatments have been tested and proposed for TPT.Shorter regimens using rifampicin or rifapentine (a long-acting rifamycin), have been shown to be as effective as isoniazid-based regimens, with higher completion rat Over the last decade, new treatments have been tested and proposed for TPT.Shorter regimens using rifampicin or rifapentine (a long-acting rifamycin), have been shown to be as effective as isoniazid-based regimens, with higher completion rates and better safety [53][54][55].A daily dose of rifampicin for 4 months (4R) [53] or 12 weeks of weekly isoniazid and rifapentine (3HP) [54] were not inferior to 9 months of isoniazid for the prevention of active TB in adults and children.Both regimens showed better completion rates and fewer serious adverse events, particularly hepatitis.More recently, a regimen combining isoniazid and rifapentine daily for one month (1HP) [55] was found not inferior to 9 months of isoniazid with a higher completion rate in adults and adolescents [56].Based on these results, the WHO issued in 2020 new recommendations for the provision of TPT in adults, adolescents and children at risk, either as living with HIV or as household contacts of people with bacteriologically confirmed pulmonary TB.These are outlined in Table 1 and the various regimens in Table 2 [23].
s and better safety [53][54][55].A daily dose of rifampicin for 4 months (4R) [53] or 12 weeks of weekly isoniazid and rifapentine (3HP) [54] were not inferior to 9 months of isoniazid for the prevention of active TB in adults and children.Both regimens showed better completion rates and fewer serious adverse events, particularly hepatitis.More recently, a regimen combining isoniazid and rifapentine daily for one month (1HP) [55] was found not inferior to 9 months of isoniazid with a higher completion rate in adults and adolescents [56].Based on these results, the WHO issued in 2020 new recommendations for the provision of TPT in adults, adolescents and children at risk, either as living with HIV or as household contacts of people with bacteriologically confirmed pulmonary TB.These are outlined in Table 1 and the various regimens in Table 2 [23].

In selected high-risk household contacts of patients with MDR-TB, preventive treatment may be considered based on an individualized risk assessment and a sound clinical justification [23].

Table 1.WHO guidelines on TB preventive therapy (source: In selected high-risk household contacts of patients with MDR-TB, preventive treatment may be considered based on an individualized risk assessment and a sound clinical justification [23]. Table 1.WHO guidelines on TB preventive therapy (source: WHO guidelines on Tuberculosis preventive treatment [23]).
HO guidelines on Tuberculosis preventive treatment [23]).


People living with HIV

Adults and adolescents living with HIV who are unlikely to have active TB should receive TPT. Treatment should al

People living with HIV
Adults and adolescents living with HIV who are unlikely to have active TB should receive TPT. Treatment should also be given to those on antiretroviral treatment, to pregnant women and to those who have previously been treated for active TB, irrespective of the degree of immunosuppression and even if TBI testing is unavailable.

be given to those on a
tiretroviral treatment, to pregnant women and to those who have previously been treated for active TB, irrespective of the degree of immunosuppression and even if TBI testing is unavailable.

Infants aged < 12 months living with HIV who are in contact with a person with TB and who are unlikely to have active TB should receive TP Infants aged < 12 months living with HIV who are in contact with a person with TB and who are unlikely to have active TB should receive TPT.
.

Children aged ≥ 12 months living with HIV who are unlikely to have active TB should be offered TPT and care if they live in a setting with Children aged ≥ 12 months living with HIV who are unlikely to have active TB should be offered TPT and care if they live in a setting with high TB transmission, regardless of contact with TB.
high TB transmission, regardless of contact with TB.

All children living with HIV who have successfully completed treatment for active TB may receive TPT.


Household contacts (regardless of All children living with HIV who have successfully completed treatment for active TB may receive TPT.

Household contacts (regardless of HIV status)
IV status)

Children aged < 5 years who are HHCs of people with bacteriologically confirmed pulmonary Children aged < 5 years who are HHCs of people with bacteriologically confirmed pulmonary TB and who are found not to have active TB should be given TPT even if TBI testing is unavailable.

and who are found not to have active TB shoul
be given TPT even if TBI testing is unavailable.

Children aged ≥ 5 years, adolescents and adults who are HHCs of people with bacteriologically confirmed pulmonary TB who are found not to Children aged ≥ 5 years, adolescents and adults who are HHCs of people with bacteriologically confirmed pulmonary TB who are found not to have active TB may be given TPT.
ave active TB may be given TPT.

In selected high-risk HHCs of patients with MDR-TB, TPT may be considered based on individualized risk assessment and a sound clinical jus In selected high-risk HHCs of patients with MDR-TB, TPT may be considered based on individualized risk assessment and a sound clinical justification.Not known _ DTG = dolutegravir, H = isoniazid, LPV-RTV = lopinavir-ritonavir, NVP = nevirapine, P = rifapentine, R = rifampicin.£ Available also in combination with pyridoxine and cotrimoxazole for people living with HIV.* One randomized trial has shown increased risk of poor birth outcomes for mothers taking isoniazid during pregnancy; however, several other studies have shown benefits of isoniazid preventive treatment; hence caution is required.$ Bleeding attributed to hypoprothrombinaemia has been reported in infants and mothers following the use of rifampicin in late pregnancy.Vitamin K is recommended for both the mother and the infant postpartum if rifampicin is used in the last few weeks of pregnancy.
ification.Not known _ DTG = dolutegravir, H = isoniazid, LPV-RTV = lopinavir-ritonavir, NVP = nevirapine, P = rifapentine, R = rifampicin.£ Available also in combination with pyridoxine and cotrimoxazole for people living with HIV.* One randomized trial has shown increased risk of poor birth outcomes for mothers taking isoniazid during pregnancy; however, several other studies have shown benefits of isoniazid preventive treatment; hence caution is required.$ Bleeding attributed to hypoprothrombinaemia has been reported in infants and mothers following the use of rifampicin in late pregnancy.Vitamin K is recommended for both the mother and the infant postpartum if rifampicin is used in the last few weeks of pregnancy.


Cost-Effectiveness of TBI Prevention

A decision analysis model based on a cohort of 10,000 adults assessing all the WHOrecommended TPT regime

Cost-Effectiveness of TBI Prevention
A decision analysis model based on a cohort of 10,000 adults assessing all the WHOrecommended TPT regimens reported that, compared with no TPT, 3HP, 4R, 3RH, 9H and 6H reduced costs (costs of medications, medical supplies, medical personnel time and diagnostic procedures) and TB-related disabilities, and 3HP was the most cost-effective [57].

reported that, compared with no TPT,
3HP, 4R, 3RH, 9H and 6H reduced costs (costs of medications, medical supplies, medical personnel time and diagnostic procedures) and TB-related disabilities, and 3HP was the most cost-effective [57].

A systematic review and meta-analysis of costs, risks, benefits and impacts of TPT among PLHIV showed that TPT was overall cost-effective for p A systematic review and meta-analysis of costs, risks, benefits and impacts of TPT among PLHIV showed that TPT was overall cost-effective for preventing active TB as compared to no TPT at all [58].Out of the sixty-one studies included, forty-five evaluated 6 to 12 months of daily isoniazid and nine considered rifamycin-based regimens.No TPT regimen was substantially more cost-effective at averting active TB than any other [58].
eventing active TB as compared to no TPT at all [58].Out of the sixty-one studies included, forty-five evaluated 6 to 12 months of daily isoniazid and nine considered rifamycin-based regimens.No TPT regimen was substantially more cost-effective at averting active TB than any other [58].

Considering the various regimens, 3HP appears as a cost-effective alternative to isoniazid preventive therapy in high-burden countries, but this Considering the various regimens, 3HP appears as a cost-effective alternative to isoniazid preventive therapy in high-burden countries, but this is largely dependent on the price of rifapentine, local willingness to pay and the capacity to obtain a high completion rate (>85%) [59,60].In high-income low-TB-burden countries, such as the United States, the 3HP regimen seems to be cost-effective when compared to 9H, especially if the cost of rifapentine decreases, adherence is maintained and the treatment is targeted towards individuals at high risk of progression to active TB [61].
s largely dependent on the price of rifapentine, local willingness to pay and the capacity to obtain a high completion rate (>85%) [59,60].In high-income low-TB-burden countries, such as the United States, the 3HP regimen seems to be cost-effective when compared to 9H, especially if the cost of rifapentine decreases, adherence is maintained and the treatment is targeted towards individuals at high risk of progression to active TB [61].

Modelling studies also provided insights on potential cost-effectiveness of a new, shorter regimen.Considering the populations of PLHIV and HHCs i Modelling studies also provided insights on potential cost-effectiveness of a new, shorter regimen.Considering the populations of PLHIV and HHCs in two countries representing two distinct epidemiological contexts, Brazil (low-TB incidence and low prevalence of HIV infection and rifampicin-resistant TB) and South Africa (high-TB incidence and high prevalence of HIV infection and rifampicin-resistant TB), a regimen meeting minimal requirements (3-month duration and 80% efficacy) was highly cost-effective, and even costsaving, compared with expanding 6H [62].In the same study, an optimal regimen (1-month duration and 100% efficacy) showed further cost-saving and health gains, primarily due to improved efficacy.
two countries representing two distinct epidemiological contexts, Brazil (low-TB incidence and low prevalence of HIV infection and rifampicin-resistant TB) and South Africa (high-TB incidence and high prevalence of HIV infection and rifampicin-resistant TB), a regimen meeting minimal requirements (3-month duration and 80% efficacy) was highly cost-effective, and even costsaving, compared with expanding 6H [62].In the same study, an optimal regimen (1-month duration and 100% efficacy) showed further cost-saving and health gains, primarily due to improved efficacy.

Lastly, a systematic review estimated that targeting contacts of MDR-TB cases with preventive therapy led to a 90% reduction in the incidence of MDR Lastly, a systematic review estimated that targeting contacts of MDR-TB cases with preventive therapy led to a 90% reduction in the incidence of MDR-TB.The cost-effectiveness was highest using a moxifloxacin/ethambutol combination regimen compared to other MDR-TB preventive regimens (pyrazinamide/ethambutol, moxifloxacin monotherapy, moxifloxacin/pyrazinamide, moxifloxacin/ethionamide and moxifloxacin/PA-824) [63].
TB.The cost-effectiveness was highest using a moxifloxacin/ethambutol combination regimen compared to other MDR-TB preventive regimens (pyrazinamide/ethambutol, moxifloxacin monotherapy, moxifloxacin/pyrazinamide, moxifloxacin/ethionamide and moxifloxacin/PA-824) [63].


Programmatic Challenges

Programmatic management of TBI is emerging as a critical component of TB control programs at the country level with the vie

Programmatic Challenges
Programmatic management of TBI is emerging as a critical component of TB control programs at the country level with the view to end TB globally [7].It refers to the identification of TBI, early detection of active TB and prescription of TPT after ruling-out active TB in people at high risk of developing active TB such as recently exposed people, people with affected/suppressed immunity and migrants from high-TB incidence countries.It requires input from different components or technical units responsible for TB prevention and control, including the detection of individuals with TBI, treatment, provision of TPT, surveillance, monitoring and evaluation of the program performance [41].

to end TB globally [7].I
refers to the identification of TBI, early detection of active TB and prescription of TPT after ruling-out active TB in people at high risk of developing active TB such as recently exposed people, people with affected/suppressed immunity and migrants from high-TB incidence countries.It requires input from different components or technical units responsible for TB prevention and control, including the detection of individuals with TBI, treatment, provision of TPT, surveillance, monitoring and evaluation of the program performance [41].


TBI Screening

Optimizing screening approaches and making them accessible and available to people is one of the greatest challenges in enhancing TPT i

TBI Screening
Optimizing screening approaches and making them accessible and available to people is one of the greatest challenges in enhancing TPT implementation [7].The lack of a largely available and accessible test for TBI diagnosis with high sensitivity and specificity in resource-limited settings, and the absence of a highly reliable test to rule out TB are major challenges to decide in whom and when to start TPT.The WHO suggests a series of algorithms associating various combinations of symptoms, chest X-ray and rapid nucleic acid amplification tests to rule out TB [64].However, low access to these tests, especially chest X-ray, and operational difficulties in the routine use of TST (storage of tuberculin, need of two visits, risk of false positive in BCG vaccinated people and negative results in immune-compromised people) and IGRA (costs and need of laboratory) [65] represent a challenge for programs, particularly in low-resource settings.Therefore, in high-TB incidence and low-resource settings, the WHO recommends initiating TPT in high-risk groups (PLHIV and young child contacts) without the need to confirm TBI and to rule out active TB based on a TB symptom screening when a chest X-ray is not available.

lementation [7
.The lack of a largely available and accessible test for TBI diagnosis with high sensitivity and specificity in resource-limited settings, and the absence of a highly reliable test to rule out TB are major challenges to decide in whom and when to start TPT.The WHO suggests a series of algorithms associating various combinations of symptoms, chest X-ray and rapid nucleic acid amplification tests to rule out TB [64].However, low access to these tests, especially chest X-ray, and operational difficulties in the routine use of TST (storage of tuberculin, need of two visits, risk of false positive in BCG vaccinated people and negative results in immune-compromised people) and IGRA (costs and need of laboratory) [65] represent a challenge for programs, particularly in low-resource settings.Therefore, in high-TB incidence and low-resource settings, the WHO recommends initiating TPT in high-risk groups (PLHIV and young child contacts) without the need to confirm TBI and to rule out active TB based on a TB symptom screening when a chest X-ray is not available.


Initiating TB Preventive Therapy

The implementation of TPT, although improved in many countries and amongst certain risk groups, has still not reached th

Initiating TB Preventive Therapy
The implementation of TPT, although improved in many countries and amongst certain risk groups, has still not reached the desired levels to achieve the End-TB strategy goals.Indeed, the reported proportion of PLHIV, HHCs < 5 years and HHCs ≥ 5 years placed on TPT between 2018 and 2021 were 10.3 million (>100% of target), 1.6 million (40% of target) and 0.6 million (3% of target), respectively.Various challenges have been identified for both the initiation and completion of TPT:

desired levels to achieve the End
TB strategy goals.Indeed, the reported proportion of PLHIV, HHCs < 5 years and HHCs ≥ 5 years placed on TPT between 2018 and 2021 were 10.3 million (>100% of target), 1.6 million (40% of target) and 0.6 million (3% of target), respectively.Various challenges have been identified for both the initiation and completion of TPT:

-TPT priority, drug stock-outs or access problems: In TB-endemic areas where resources are limited, the focus is more on treating than preventing TB [66].Fea -TPT priority, drug stock-outs or access problems: In TB-endemic areas where resources are limited, the focus is more on treating than preventing TB [66].Fear of drug stockouts, especially in peripheral centers, had been identified as the main cause of noninitiation of isoniazid preventive therapy [67].In addition, operational and logistical issues may also lead to limited access to TBI screening and to TPT [68]; -Lack of qualified human resources: The lack of qualified health care workers or the absence of training on how to prescribe TPT and convince asymptomatic individuals to undertake TBI screening or to take treatment may lead to distrust in health care workers [69,70]; -Approach to screening and TPT: Routine screening for TBI may create anxiety and fear of stigma for individuals who do not feel sick.The WHO recommends decentralized, family-centered and integrated models of care to deliver services to children, adolescents and adults exposed to TB [71]; -Diagnostic of TBI and active TB: The inherent limitations in the currently available tests for diagnosis of TBI as well as those for ruling out active TB and their limited availability in resource-poor countries are hampering wide programmatic management of TBI and may lead to the emergence of drug-resistance if TPT is not appropriately prescribed [72]; -Availability of shortened regimens: The current high cost of rifapentine and the limited access to appropriate drug formulations, especially the dispersible rifapentine for infants, fixed-dose combinations for HP [41] and single-dose of rifampicin for 4R [23] are a further limit to the wide provision of TPT; -Monitoring and evaluation: Few low-and middle-income countries (LMICs) have an established system for monitoring and evaluating the implementation of TPT [73].
of drug stockouts, especially in peripheral centers, had been identified as the main cause of noninitiation of isoniazid preventive therapy [67].In addition, operational and logistical issues may also lead to limited access to TBI screening and to TPT [68]; -Lack of qualified human resources: The lack of qualified health care workers or the absence of training on how to prescribe TPT and convince asymptomatic individuals to undertake TBI screening or to take treatment may lead to distrust in health care workers [69,70]; -Approach to screening and TPT: Routine screening for TBI may create anxiety and fear of stigma for individuals who do not feel sick.The WHO recommends decentralized, family-centered and integrated models of care to deliver services to children, adolescents and adults exposed to TB [71]; -Diagnostic of TBI and active TB: The inherent limitations in the currently available tests for diagnosis of TBI as well as those for ruling out active TB and their limited availability in resource-poor countries are hampering wide programmatic management of TBI and may lead to the emergence of drug-resistance if TPT is not appropriately prescribed [72]; -Availability of shortened regimens: The current high cost of rifapentine and the limited access to appropriate drug formulations, especially the dispersible rifapentine for infants, fixed-dose combinations for HP [41] and single-dose of rifampicin for 4R [23] are a further limit to the wide provision of TPT; -Monitoring and evaluation: Few low-and middle-income countries (LMICs) have an established system for monitoring and evaluating the implementation of TPT [73].

In addition, the reporting requirements by different donor agencies, which are not harmonized with international and national indicators, may contribute to unnecessary program overload [73].


Further Research and Future Direction

Improved point-of-care diagnostic tests that can reliably distinguish between TBI and active TB, combined with the capa In addition, the reporting requirements by different donor agencies, which are not harmonized with international and national indicators, may contribute to unnecessary program overload [73].

Further Research and Future Direction
Improved point-of-care diagnostic tests that can reliably distinguish between TBI and active TB, combined with the capacity to assess the risk of active TB development would certainly be a major asset for TB prevention on a global scale.IGRA testing offers better potential to confirm and treat TBI than TST, but implementation remains limited (due to the lack of appropriate laboratory equipment and technical expertise) [74].Further research is needed to better distinguish between TBI and active TB and to identify predictive biomarkers of disease progression.A recent pooled meta-analysis has reported that current candidate biomarkers have the ability to accurately reflect active TB risk and meet the WHO target product profile (including minimum sensitivity and specificity of 75%, and optimal sensitivity and specificity of 90%) mainly when considering a short-term risk of TB (period of 3 to 6 months after TBI) [46].

ty to assess the risk of active TB dev
lopment would certainly be a major asset for TB prevention on a global scale.IGRA testing offers better potential to confirm and treat TBI than TST, but implementation remains limited (due to the lack of appropriate laboratory equipment and technical expertise) [74].Further research is needed to better distinguish between TBI and active TB and to identify predictive biomarkers of disease progression.A recent pooled meta-analysis has reported that current candidate biomarkers have the ability to accurately reflect active TB risk and meet the WHO target product profile (including minimum sensitivity and specificity of 75%, and optimal sensitivity and specificity of 90%) mainly when considering a short-term risk of TB (period of 3 to 6 months after TBI) [46].

Along with improved diagnostics, there is a need to continue the search for a shorter or ultra-short (<1 month), safe and well-tolerated TPT that can be administe Along with improved diagnostics, there is a need to continue the search for a shorter or ultra-short (<1 month), safe and well-tolerated TPT that can be administered to all patients without concern for drug-drug interactions.While waiting for the results of the currently conducted trials, uncertainty persists regarding the optimal TPT strategies in communities with high rates of isoniazid-or fluoroquinolone-resistance [41].Table 3 summarizes the current studies on TPT with new drugs such as bedaquiline, pretomanid or delamanid.Of note, we found studies in high-income settings as well as in low-and middle-income settings and all populations were covered (PLHIV, LGBT, MDR-TB).In addition, many ongoing studies are about shorter or ultra-short treatment with different administration strategies (daily 1HP and 3 times/week 1 HP, for example).
ed to all patients without concern for drug-drug interactions.While waiting for the results of the currently conducted trials, uncertainty persists regarding the optimal TPT strategies in communities with high rates of isoniazid-or fluoroquinolone-resistance [41].Table 3 summarizes the current studies on TPT with new drugs such as bedaquiline, pretomanid or delamanid.Of note, we found studies in high-income settings as well as in low-and middle-income settings and all populations were covered (PLHIV, LGBT, MDR-TB).In addition, many ongoing studies are about shorter or ultra-short treatment with different administration strategies (daily 1HP and 3 times/week 1 HP, for example).

It would be helpful to consider the potential impact of different TBI management strategies on different population groups, such as those at high risk for progression It would be helpful to consider the potential impact of different TBI management strategies on different population groups, such as those at high risk for progression to active TB in high-income countries or LMICs, those with limited access to health care and those in LMICs where the burden of TB is the highest.
to active TB in high-income countries or LMICs, those with limited access to health care and those in LMICs where the burden of TB is the highest.

In the meantime, using the currently available tools more efficiently and better targeting resources to those most at risk of active TB development or reactivation wo In the meantime, using the currently available tools more efficiently and better targeting resources to those most at risk of active TB development or reactivation would go a long way toward reducing the global TB burden [75].
ld go a long way toward reducing the global TB burden [75].


Conclusions

Tuberculosis infection is a complex and heterogeneous condition resulting from the interaction between the organism and the host immune response [8].TBI a

Conclusions
Tuberculosis infection is a complex and heterogeneous condition resulting from the interaction between the organism and the host immune response [8].TBI affects one-quarter of the world's population and constitutes the reservoir of active TB.Meeting the goals of the WHO End-TB strategy requires a multipronged approach that includes the systematic screening of high-risk populations, and targeted provision of preventive therapy with an effective monitoring and evaluation system.The global scale-up of TPT, especially in LMICs, requires wide access to diagnostic and prevention tools to permit the wide scale-up of this cornerstone strategy for ending TB globally, through adequate funding, and, more importantly, strong political commitment.

ects one-qua
ter of the world's population and constitutes the reservoir of active TB.Meeting the goals of the WHO End-TB strategy requires a multipronged approach that includes the systematic screening of high-risk populations, and targeted provision of preventive therapy with an effective monitoring and evaluation system.The global scale-up of TPT, especially in LMICs, requires wide access to diagnostic and prevention tools to permit the wide scale-up of this cornerstone strategy for ending TB globally, through adequate funding, and, more importantly, strong political commitment.

Figure 1 .
1
Figure 1.Spectrum of TB infection.


Figure 1 .
1
Figure 1.Spectrum of TB infection.


Table 2 .
2
[23]reventive therapy recommended by the WHO (source: WHO guidelines on Tuberculosis preventive treatment[23]).
MedicinesIsoniazid 6HIsoniazid + Rifapentine 3HPIsoniazid + Rifampicin 3HRRifampic

Table 3 .
Ongoing clinical trials on tuberculosis preventive treatment.